Novo Nordisk used its 2026 Capital Markets Day to outline a 2030 strategy aimed at restoring growth momentum after investor skepticism. Executives said Novo plans to launch more than five multi-blockbusters each year through 2030, anchored in obesity and diabetes Phase III programs, while also preparing for the eventual loss of U.S. patent exclusivity for semaglutide in 2032. Analysts cited in the report said the strategy fell short of what investors wanted, noting growth assumptions and the possibility that the outlined targets are already priced in. The semaglutide loss of exclusivity framed the company’s roadmap and increased emphasis on pipeline diversification and potential M&A as external growth support. For biotech and pharma watchers, the update matters because it signals how large-cap metabolic players are repositioning ahead of GLP-1 competitive intensity. Novo’s emphasis on multi-blockbuster volume and long-range risk-adjusted pipeline sales illustrates the scale of execution now expected from metabolic franchises.